Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial
-
Published:2023-10
Issue:
Volume:
Page:
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Boschheidgen Matthias, Albers Peter, Schlemmer Heinz-Peter, Hellms Susanne, Bonekamp David, Sauter Andreas, Hadaschik Boris, Krilaviciute Agne, Radtke Jan Philipp, Seibold Petra, Lakes Jale, Arsov Christian, Gschwend Jürgen E., Herkommer Kathleen, Makowski Marcus, Kuczyk Markus A., Wacker Frank, Harke Nina, Debus Jürgen, Körber Stefan A., Benner Axel, Kristiansen Glen, Giesel Frederik L., Antoch Gerald, Kaaks Rudolf, Becker Nikolaus, Schimmöller LarsORCID
Reference29 articles.
1. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer;Hugosson;Eur Urol,2019 2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial;Nordström;Lancet Oncol,2021 3. MRI-targeted or standard biopsy in prostate cancer screening;Eklund;N Engl J Med,2021 4. Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial;Arsov;Eur Urol,2013 5. MRI grading for the prediction of prostate cancer aggressiveness;Boschheidgen;Eur Radiol,2022
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|